734-936-8000 - Service Desk | Request Support

SARS-CoV-2 Vaccines

To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.

Step Status
Educational Materials ✘
Evaluation ✘
Release Date: Fri, 12/18/20
Termination Date: Fri, 12/31/21
Credits: 1
Description:

SARS-CoV-2 Vaccines



Presenter: Amy Hepper, MDThis lecture was originally presented during General Medicine Clinical Conference/Journal Club (2020) held on 12/01/2020.

There are no relevant financial relationships to disclose for this activity.

Target Audience:

Access to content is limited to Michigan Medicine or those with a level 1 sign-on.

This activity is appropriate for Nurse Practitioners, Physician Assistants, Physicians in the fields of General Medicine, Internal Medicine, Pediatrics, Primary Care.
Accreditation and Credit Designation:

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Info:

Bibliography CME talk: SARS-CoV-2 Vaccines 12-1-2020

  1. Dal-Ré, R., Caplan, A. L., Gluud, C., & Porcher, R. (2020). Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine. Annals of internal medicine, M20-7357. Advance online publication. https://doi.org/10.7326/M20-7357
  2. Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., Schmidt, S. D., Swanson, P. A., 2nd, Padilla, M., … mRNA-1273 Study Group (2020). An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. The New England journal of medicine, 383(20), 1920–1931. https://doi.org/10.1056/NEJMoa2022483
  3. McClung, N., Chamberland, M., Kinlaw, K., Bowen Matthew, D., Wallace, M., Bell, B. P., Lee, G. M., Talbot, H. K., Romero, J. R., Oliver, S. E., & Dooling, K. (2020). The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.  Morbidity and mortality weekly report, 69(47), 1782–1786. https://doi.org/10.15585/mmwr.mm6947e3
  4. Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P. Y., Türeci, Ö., Tompkins, K. R., Walsh, E. E., Frenck, R., … Jansen, K. U. (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 586(7830), 589–593. https://doi.org/10.1038/s41586-020-2639-4
  5. Pollard, TD Cell Biology Third Edition. Elsevier, Inc.
  6. V’kovski, P., Kratzel, A., Steiner, S. et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol (2020). https://doi.org/10.1038/s41579-020-00468-6
  7. Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A. K., Grützner, J., Boesler, C., Rosenbaum, C., Kühnle, M. C., … Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 586(7830), 594–599. https://doi.org/10.1038/s41586-020-2814-7
  8. Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., Yang, Y., Chen, W., Gao, X., You, W., Wang, X., Wang, Z., Shi, Z., Wang, Y., Yang, X., Zhang, L., … Yang, X. (2020). Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA, 324(10), 951–960. https://doi.org/10.1001/jama.2020.15543
  9. Zhu, F. C., Li, Y. H., Guan, X. H., Hou, L. H., Wang, W. J., Li, J. X., Wu, S. P., Wang, B. S., Wang, Z., Wang, L., Jia, S. Y., Jiang, H. D., Wang, L., Jiang, T., Hu, Y., Gou, J. B., Xu, S. B., Xu, J. J., Wang, X. W., Wang, W., … Chen, W. (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London, England), 395(10240), 1845–1854. https://doi.org/10.1016/S0140-6736(20)31208-3
  10. Zhu, F. C., Guan, X. H., Li, Y. H., Huang, J. Y., Jiang, T., Hou, L. H., Li, J. X., Yang, B. F., Wang, L., Wang, W. J., Wu, S. P., Wang, Z., Wu, X. H., Xu, J. J., Zhang, Z., Jia, S. Y., Wang, B. S., Hu, Y., Liu, J. J., Zhang, J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 396(10249), 479–488. https://doi.org/10.1016/S0140-6736(20)31605-6

Credits available:

AMA PRA Category 1: 1.00
Participation: 1.00